Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | POLR1A | O95602 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21880092 | 0.86 | USP30 (0.41) | POLR1AUSP30GABRA5PARP1ADORA2A | |
| SCHEMBL21880058 | 0.85 | KDM4E (0.33) | — | |
| SCHEMBL21880034 | 0.83 | ADORA2A (0.38) | POLR1AUSP30GABRA5PARP1ADORA2A | |
| SCHEMBL21879937 | 0.82 | HDAC4 (0.39) | POLR1AUSP30GABRA5PARP1ADORA2A | |
| SCHEMBL23931020 | 0.79 | GABRA5 (0.36) | POLR1AUSP30GABRA5PARP1LMNA | |
| SCHEMBL21879973 | 0.79 | USP30 (0.39) | PIK3CDPOLR1AUSP30GABRA5PARP1 | |
| SCHEMBL23930977 | 0.77 | USP30 (0.44) | POLR1AUSP30GABRA5PARP1ADORA2A | |
| SCHEMBL23930984 | 0.77 | USP30 (0.40) | POLR1AUSP30PARP1ADORA2AADORA2B | |
| SCHEMBL21879895 | 0.76 | USP30 (0.39) | POLR1AUSP30PARP1ADORA2AADORA2B | |
| SCHEMBL29902371 | 0.76 | USP30 (0.47) | POLR1AUSP30GABRA5PARP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| EP-4067343-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | PIK3CD 3736/4885POLR1A 751/4885USP30 3423/4885 |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | MYB, MLX, EP300 | PIK3CD 3742/4885POLR1A 747/4885USP30 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.